We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Pharmacoproteomics identifies combinatorial therapy targets for diffuse large B cell lymphoma.
- Authors
Goldstein, Rebecca L.; Shao Ning Yang; Taldone, Tony; Chang, Betty; Gerecitano, John; Elenitoba-Johnson, Kojo; Shaknovich, Rita; Tam, Wayne; Leonard, John P.; Chiosis, Gabriela; Cerchietti, Leandro; Melnick, Ari; Yang, Shao Ning
- Abstract
Rationally designed combinations of targeted therapies for refractory cancers, such as activated B cell-like diffuse large B cell lymphoma (ABC DLBCL), are likely required to achieve potent, durable responses. Here, we used a pharmacoproteomics approach to map the interactome of a tumor-enriched isoform of HSP90 (teHSP90). Specifically, we chemically precipitated teHSP90-client complexes from DLBCL cell lines with the small molecule PU-H71 and found that components of the proximal B cell receptor (BCR) signalosome were enriched within teHSP90 complexes. Functional assays revealed that teHSP90 facilitates BCR signaling dynamics by enabling phosphorylation of key BCR signalosome components, including the kinases SYK and BTK. Consequently, treatment of BCR-dependent ABC DLBCL cells with PU-H71 attenuated BCR signaling, calcium flux, and NF-κB signaling, ultimately leading to growth arrest. Combined exposure of ABC DLBCL cell lines to PU-H71 and ibrutinib, a BCR pathway inhibitor, more potently suppressed BCR signaling than either drug alone. Correspondingly, PU-H71 combined with ibrutinib induced synergistic killing of lymphoma cell lines, primary human lymphoma specimens ex vivo, and lymphoma xenografts in vivo, without notable toxicity. Together, our results demonstrate that a pharmacoproteome-driven rational combination therapy has potential to provide more potent BCR-directed therapy for ABC DLCBL patients.
- Subjects
PROTEOMICS; DIFFUSE large B-cell lymphomas; PHOSPHORYLATION; LYMPHOMAS; XENOGRAFTS; KINASES; CELL lines; PROTEIN metabolism; ANTINEOPLASTIC agents; B cell lymphoma; CELLULAR signal transduction; HETEROCYCLIC compounds; PROTEIN-tyrosine kinases; PROTEINS; PURINES; SIGNAL peptides; CHEMICAL inhibitors; PHARMACODYNAMICS
- Publication
Journal of Clinical Investigation, 2015, Vol 125, Issue 12, p4559
- ISSN
0021-9738
- Publication type
journal article
- DOI
10.1172/JCI80714